<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02857920</url>
  </required_header>
  <id_info>
    <org_study_id>NK-Bevacizumab</org_study_id>
    <nct_id>NCT02857920</nct_id>
  </id_info>
  <brief_title>Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors</brief_title>
  <official_title>Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fuda Cancer Hospital, Guangzhou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shenzhen Hank Bioengineering Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fuda Cancer Hospital, Guangzhou</source>
  <brief_summary>
    <textblock>
      The aim of this study is the safety and efficacy of Bevacizumab plus allogeneic natural&#xD;
      killer (NK) immunotherapy to many kinds of recurrent solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      By enrolling patients with recurrent solid tumors adapted to enrolled criteria, this study&#xD;
      will document for the first time the safety and the short and long term efficacy of the&#xD;
      combined therapy using Bevacizumab and NK cells.&#xD;
&#xD;
      The safety will be evaluated by statistics of adverse reactions. The efficacy will be&#xD;
      evaluated according to local relief degree, progress free survival (PFS) and overall survival&#xD;
      (OS).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2016</start_date>
  <completion_date type="Actual">August 1, 2019</completion_date>
  <primary_completion_date type="Actual">August 1, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>1 year</time_frame>
    <description>PFS was defined as the interval between treatment initiation and local relapse</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OS</measure>
    <time_frame>3 years</time_frame>
    <description>OS was calculated as the interval from treatment initiation to death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor size</measure>
    <time_frame>3 months</time_frame>
    <description>The tumor responses of the enrolled patients were assessed by CT in accordance with RECIST v1.1.Institute Common Terminology Criteria for Adverse Events (v4.0).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CTC</measure>
    <time_frame>3 months</time_frame>
    <description>The absolute number of CD45-CK+ CD326+ cells was used to quantitate the CTC levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD-1</measure>
    <time_frame>3 months</time_frame>
    <description>Peripheral blood (6 mL) was obtained from healthy donors and patients before treatment and 90 days after treatment for the detection of PD-1</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Malignant Solid Tumour</condition>
  <arm_group>
    <arm_group_label>Bevacizumab and NK immunotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group, the patients will receive regular Bevacizumab treatment in combination with multiple NK immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bevacizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In this group, the patients will receive regular Bevacizumab treatment to control the tumor growth. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>7.5 mg/kg, i.v, once every 3 weeks (continuous)</description>
    <arm_group_label>Bevacizumab</arm_group_label>
    <arm_group_label>Bevacizumab and NK immunotherapy</arm_group_label>
    <other_name>Anti-VEGF, Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NK immunotherapy</intervention_name>
    <description>Each treatment: 8~10 billion cells in all, transfusion in 3 times, i.v.</description>
    <arm_group_label>Bevacizumab and NK immunotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All standard therapies have failed according to NCCN guidelines or the patient refuses&#xD;
             standard therapies after cancer recurrence&#xD;
&#xD;
          -  Body tumor 1-6, the maximum tumor length &lt; 5 cm&#xD;
&#xD;
          -  KPS ≥ 70, lifespan &gt; 6 months&#xD;
&#xD;
          -  Platelet count ≥ 80×109/L，white blood cell count ≥ 3×109/L, neutrophil count ≥&#xD;
             2×109/L, hemoglobin ≥ 80 g/L&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with cardiac pacemaker&#xD;
&#xD;
          -  Patients with brain metastasis&#xD;
&#xD;
          -  Patients with grade 3 hypertension or diabetic complication, severe cardiac and&#xD;
             pulmonary dysfunction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jibing Chen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fuda Cancer Hospital, Guangzhou</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fuda cancer institute of Fuda cancer hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510665</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 3, 2016</study_first_submitted>
  <study_first_submitted_qc>August 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2016</study_first_posted>
  <last_update_submitted>September 10, 2020</last_update_submitted>
  <last_update_submitted_qc>September 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vascular Endothelial Growth Factor (VEGF) antibody</keyword>
  <keyword>solid tumor</keyword>
  <keyword>NK Immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

